Compass Pathways Plc
$ 7.99
1.78%
24 Feb - close price
- Market Cap 767,176,000 USD
- Current Price $ 7.99
- High / Low $ 8.03 / 7.63
- Stock P/E N/A
- Book Value 0.39
- EPS -2.72
- Next Earning Report 2026-02-26
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.38 %
- ROE -2.06 %
- 52 Week High 8.90
- 52 Week Low 2.25
About
COMPASS Pathways plc is a mental health care company in the United Kingdom and the United States. The company is headquartered in Cheshire, the United Kingdom.
Analyst Target Price
$19.42
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-10-30 | 2025-07-30 | 2025-05-06 | 2025-02-26 | 2024-10-31 | 2024-08-01 | 2024-05-08 | 2024-02-29 | 2023-11-02 | 2023-08-03 | 2023-05-11 | 2023-02-28 |
| Reported EPS | -0.3836 | -0.4114 | -0.4185 | -0.63 | -0.56 | -0.56 | -0.55 | -0.53 | -0.67 | -0.62 | -0.57 | -0.73 |
| Estimated EPS | -0.3955 | -0.4228 | -0.49 | -0.63 | -0.57 | -0.52 | -0.49 | -0.33 | -0.43 | -0.69 | -0.68 | -0.59 |
| Surprise | 0.0119 | 0.0114 | 0.0715 | 0 | 0.01 | -0.04 | -0.06 | -0.2 | -0.24 | 0.07 | 0.11 | -0.14 |
| Surprise Percentage | 3.0088% | 2.6963% | 14.5918% | 0% | 1.7544% | -7.6923% | -12.2449% | -60.6061% | -55.814% | 10.1449% | 16.1765% | -23.7288% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-26 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.41 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CMPS
2026-02-24 11:53:01
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company specializing in mental health innovation, announced its management will attend the TD Cowen 46th Annual Healthcare Conference. The conference will take place in Boston, MA, from March 2-4, 2026, where Compass Pathways will participate in a fireside chat on March 3, 2026, at 10:30am ET. A live audio webcast and replay will be available through the company's investors section.
2026-02-23 14:25:25
Compass Pathways PLC is projected to report a loss of 39 cents per share. This earnings preview highlights the expected financial performance of the company. The information is provided by Reuters via Refinitiv.
2026-02-23 13:38:40
Compass Pathways is seeking FDA approval for its psilocybin-based drug, COMP360, for treatment-resistant depression, following positive phase 3 results. However, signs of internal disagreement within HHS and officials' cautious views on psychedelics create uncertainty for its approval. Despite setbacks faced by Compass and other psychedelic developers, the pharmaceutical industry shows growing interest in this treatment area, as evidenced by large investments and the success of non-classic psychedelics like J&J's Spravato.
2026-02-21 11:47:19
Compass Pathways (CMPS), a mental healthcare company, is developing psilocybin therapy for depression and other conditions, currently in Phase III trials. Despite an 84% drop from its all-time high, RBC Capital Markets rated CMPS "outperform" with a $23 target, and analysts predict a significant surge. The stock is considered high-risk due to regulatory uncertainties but has sufficient liquidity to complete its trials.
2026-02-21 09:55:54
Columbia University researchers have found that a single dose of psilocybin can change brain connectivity to alleviate symptoms of body dysmorphic disorder (BDD). A pilot study with eight adults showed increased connectivity in various brain networks, with those exhibiting the greatest neural strengthening experiencing the most improvement in BDD symptoms. While preliminary, these findings suggest psilocybin may help restore adaptive cognitive and emotional functioning in psychiatric disorders.
2026-02-19 19:21:32
LifeSci Capital initiated coverage on COMPASS Pathways plc (CMPS) with a Buy rating and a $15 price target, while RBC Capital raised its price target to $21 and maintained an Outperform rating. These updates follow a Psychedelics Symposium and adjustments to the CMPS model, reflecting insights on pricing and barriers to generic entry in the psychedelic therapy market. The company also announced FDA approval for its IND application for COMP360, enabling a Phase 2b/3 trial for PTSD, marking its entry into another significant psychiatric indication.
